Deciphera Pharmaceuticals (DCPH)
(Delayed Data from NSDQ)
$14.62 USD
-0.05 (-0.34%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $14.61 -0.01 (-0.07%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
DCPH 14.62 -0.05(-0.34%)
Will DCPH be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for DCPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DCPH
Deciphera Pharmaceuticals, Inc. (DCPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Why Is Biogen Inc. (BIIB) Up 2.6% Since Last Earnings Report?
DCPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Up 20.8% Since Last Earnings Report?
Wall Street Analysts Think Deciphera Pharmaceuticals, Inc. (DCPH) Could Surge 48.49%: Read This Before Placing a Bet
Wall Street Analysts Believe Deciphera Pharmaceuticals, Inc. (DCPH) Could Rally 59.63%: Here's is How to Trade
Other News for DCPH
Piper Sandler Sticks to Their Buy Rating for Deciphera Pharmaceuticals (DCPH)
Commit To Purchase Deciphera Pharmaceuticals At $7.50, Earn 15.7% Annualized Using Options
Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum
Analysts Have Conflicting Sentiments on These Healthcare Companies: Deciphera Pharmaceuticals (DCPH) and Shockwave Medical (SWAV)
Cantor sees strong year ahead for oncology M&A